HC
BHVN

Henshaw Capital’s Biohaven Pharmaceutical Holding Company Ltd. BHVN Stock Holding History

Henshaw Capital’s Portfolio BHVN Stock Details BHVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-2,974
Closed -$353K – 325
2022
Q1 		$353K Hold
2,974
– – 0.02% 215
2021
Q4 		$410K Buy
2,974
+617
+26% +$78.5K 0.02% 200
2021
Q3 		$327K Buy
+2,357
New +$294K 0.02% 239

Other funds holding BHVN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Stifel Financial
Stifel Financial St. Louis, Missouri $120B AUM 27.84% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.76B AUM 62.41% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Henshaw Capital's BHVN Position: Q2 2022 in Review

Henshaw Capital sold out of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) in Q2 2022, closing a stake of 2,974 shares — an estimated $353K sold.

Henshaw Capital first reported a position in BHVN in Q3 2021 and held it in 3 quarters. The position peaked at $410K in Q4 2021. 329 funds tracked by Wall St. Rank hold BHVN as of Q2 2022.

  • Henshaw Capital reported no remaining Biohaven Pharmaceutical Holding Company Ltd. position as of Q2 2022 after selling out during the quarter.
  • Henshaw Capital sold 2,974 Biohaven Pharmaceutical Holding Company Ltd. shares in Q2 2022, an estimated $353K.
  • Henshaw Capital first reported a position in Biohaven Pharmaceutical Holding Company Ltd. in Q3 2021 and held it in 3 quarters.
  • Henshaw Capital's Biohaven Pharmaceutical Holding Company Ltd. position peaked at $410K in Q4 2021.
  • 329 funds tracked by Wall St. Rank held Biohaven Pharmaceutical Holding Company Ltd. as of Q2 2022.

Based on Henshaw Capital's 13F filing for Q2 2022, filed 28 May 2026.